New Research Demonstrates Claims that the Wuhan Institute of Virology had no cases of COVID-19 are not credible

Rhea-AI Summary

Atossa Therapeutics, led by Dr. Steven Quay, published research challenging the claim that the Wuhan Institute of Virology had no COVID-19 cases. The study highlights a statistical improbability given the 4.4% prevalence of COVID-19 in Wuhan during early 2020. The researchers argue that proper testing would likely have revealed positive cases among the 590 staff members at WIV. This analysis raises serious questions about the integrity of WIV's reported COVID cases.

Positive

• Research by Atossa Therapeutics provides critical insights into COVID-19 testing claims.
• Dr. Steven Quay's reputation as a prominent scientist may enhance investor confidence.

Negative

• The research findings could lead to scrutiny of Atossa's credibility in the biopharmaceutical sector.
• Potential negative market reactions due to association with controversial COVID-19 origins theories.

SEATTLE, May 27, 2021 /PRNewswire/ -- DRASTIC Investigator Gilles Demaneuf and Physician-Scientist Dr. Steven C. Quay, M.D., Ph.D., CEO of Atossa Therapeutics (NASDAQ: ATOS), have published new research that addresses the question of whether the claim that there were no COVID cases at the Wuhan Institute of Virology (WIV) is legitimate. Given that it has been reported there were about 590 staff members working at the WIV at that time and the documented prevalence of COVID in Wuhan during the first half of 2020 of 4.4%, it is statistically impossible that there were no cases. The research can be read here.

"The purpose of our analysis was to try to reconcile the reports from the U.S. State Department of early COVID cases in the fall of 2019 at the Wuhan Institute of Virology with the pronouncements by the WIV that they had no cases whatsoever," stated Dr. Quay. "We determined that with 4.4% of the general population of Wuhan testing positive at about the same time, the probability that nobody would have tested positive at the WIV is extremely small, unless so few people were tested there that the testing exercise itself was largely flawed and irrelevant. An island of uninfected people at the WIV could not have existed in Wuhan at that time."

"This study cannot address directly the timing of early cases," continued Mr. Demaneuf. "But whether infected from the laboratory or from the community, you can be sure that a properly designed testing of staff and students would have returned many positive cases."

About Steven Quay, M.D., Ph.D.

Dr. Steven Quay has 360+ published contributions to medicine and has been cited over 10,000 times, placing him in the top 1% of scientists worldwide. He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have helped over 80 million people. He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus, available here.  He is the CEO of Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for treating breast cancer and COVID-19.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. A TEDx talk he delivered on breast cancer prevention has been viewed over 220,000 times.  For more information, visit www.DrQuay.com

About Gilles Demaneuf

Gilles Demaneuf (MScEng, Applied Maths) is a data scientist and analyst within DRASTIC, a multi-disciplinary community of scientists, data specialists, and biologists who have been working on the possible origins of SARS-CoV-2 since early 2020. For more information, visit Gilles Demaneuf

Public Relations Contact:

Dunn Pellier Media| t: 323.481.2307
11620 Wilshire Blvd., 9th Floor, Los Angeles, CA 90025
Jenn@dunnpelliermedia.com  
nicole@dunnpelliermedia.com 

View original content:http://www.prnewswire.com/news-releases/new-research-demonstrates-claims-that-the-wuhan-institute-of-virology-had-no-cases-of-covid-19-are-not-credible-301301156.html

SOURCE Dr. Steven Quay

FAQ

What did Atossa Therapeutics find in their research about Wuhan Institute of Virology?

Atossa Therapeutics' research indicates that the claim of no COVID-19 cases at the Wuhan Institute of Virology is statistically improbable given the prevalence of COVID-19 in Wuhan at that time.

Who conducted the study on COVID-19 cases at the Wuhan Institute?

The study was conducted by Gilles Demaneuf and Dr. Steven Quay, M.D., Ph.D., CEO of Atossa Therapeutics.

When was the research regarding the Wuhan Institute of Virology published?

The research was published on May 27, 2021.

How does this research impact Atossa Therapeutics' stock?

The research may impact investor confidence either positively, by showcasing scientific rigor, or negatively, due to potential controversy.

What is the significance of the 4.4% COVID-19 prevalence in the research?

The 4.4% prevalence indicates a statistical improbability that no COVID-19 cases occurred at the Wuhan Institute, raising questions about their testing validity.